Fukumoto M - Search Results

1

The proliferative activity of ovarian tumors of low malignant potential differs from that of ovarian carcinoma.

Nakayama K, Takebayashi Y, Hata K, Fujiwaki R, Iida K, Fukumoto M, Miyazaki K. Nakayama K, et al. Among authors: fukumoto m. Anticancer Res. 2003 Nov-Dec;23(6C):4657-62. Anticancer Res. 2003. PMID: 14981910

2

Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin.

Nakayama K, Takebayashi Y, Nakayama S, Hata K, Fujiwaki R, Fukumoto M, Miyazaki K. Nakayama K, et al. Among authors: fukumoto m. Cancer Lett. 2003 Mar 31;192(2):227-35. doi: 10.1016/s0304-3835(02)00686-9. Cancer Lett. 2003. PMID: 12668287

3

Allelotypes as potential prognostic markers in ovarian carcinoma treated with cisplatin-based chemotherapy.

Nakayama S, Nakayama K, Takebayashi Y, Hata K, Fujiwaki R, Fukumoto M, Miyazaki K. Nakayama S, et al. Among authors: fukumoto m. Int J Mol Med. 2003 May;11(5):621-5. Int J Mol Med. 2003. PMID: 12684700

4

Ovarian epithelial tumors of low malignant potential: are they precursors of ovarian carcinoma?

Fukumoto M, Nakayama K. Fukumoto M, et al. Pathol Int. 2006 May;56(5):233-9. doi: 10.1111/j.1440-1827.2006.01960.x. Pathol Int. 2006. PMID: 16669871 Review.

5

Expression of thymidine phosphorylase and vascular endothelial growth factor in epithelial ovarian cancer: correlation with angiogenesis and progression of the tumor.

Hata K, Fujiwaki R, Nakayama K, Maede Y, Fukumoto M, Miyazaki K. Hata K, et al. Among authors: fukumoto m. Anticancer Res. 2000 Sep-Oct;20(5C):3941-9. Anticancer Res. 2000. PMID: 11268481

6

Allelic loss at 19q12 and Xq11-12 predict an adverse clinical outcome in patients with mucinous ovarian tumours of low malignant potential.

Nakayama K, Takebayashi Y, Hata K, Fujiwaki R, Iida K, Fukumoto M, Miyazaki K. Nakayama K, et al. Among authors: fukumoto m. Br J Cancer. 2004 Mar 22;90(6):1204-10. doi: 10.1038/sj.bjc.6601681. Br J Cancer. 2004. PMID: 15026802 Free PMC article.

7

Fractional allelic loss as a potential biomarker of risk prediction in early-stage mucinous ovarian tumors of low malignant potential.

Nakayama K, Nakayama N, Ishibashi M, Yeasmin S, Fukumoto M, Miyazaki K. Nakayama K, et al. Among authors: fukumoto m. Eur J Gynaecol Oncol. 2009;30(1):16-9. Eur J Gynaecol Oncol. 2009. PMID: 19317250

8

Genetic classification of ovarian carcinoma based on microsatellite analysis: relationship to clinicopathological features and patient survival.

Huan Z, Nakayama K, Nakayama N, Ishibashi M, Yeasmin S, Katagiri A, Purwana IN, Iida K, Maruyama R, Fukumoto M, Miyazaki K. Huan Z, et al. Among authors: fukumoto m. Oncol Rep. 2008 Mar;19(3):775-81. Oncol Rep. 2008. PMID: 18288415

9

Expression of the thymidine phosphorylase gene in epithelial ovarian cancer.

Hata K, Kamikawa T, Arao S, Tashiro H, Katabuchi H, Okamura H, Fujiwaki R, Miyazaki K, Fukumoto M. Hata K, et al. Among authors: fukumoto m. Br J Cancer. 1999 Apr;79(11-12):1848-54. doi: 10.1038/sj.bjc.6690294. Br J Cancer. 1999. PMID: 10206303 Free PMC article.

10

Expression of thymidine phosphorylase in human cervical cancer.

Hata K, Takebayashi Y, Iida K, Fujiwaki R, Fukumoto M, Miyazaki K. Hata K, et al. Among authors: fukumoto m. Anticancer Res. 1999 Jan-Feb;19(1B):709-16. Anticancer Res. 1999. PMID: 10216481

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

752 results

Search Page

Filters